6 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 12 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 6, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Pituitary Neoplasms: new trials by email Literature Review of Pituitary Neoplasms trials Research Report on Pituitary Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease | Phase 3 | Not yet recruiting | University College, London | 82 | 2026-09-01 | 2026-10-01 |
| Safety and Potency of a High Cabergoline Dosage in Microprolactinomas Cabergoline - Prolactinoma, Prolactin Excess | Phase 3 | Recruiting | University of Sao Paulo General Hospital | 70 | 2026-03-04 | 2026-03-13 |
| The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas Radiotherapy plus temozolomide, Radiotherapy plus placebo - Pituitary Adenomas | Phase 2 / Phase 3 | Unknown | Peking Union Medical College Hospital | 150 | 2020-02-10 | 2020-01-28 |
| Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection - Acromegaly Due to Pituitary Adenoma | Phase 3 | Unknown | Samsung Medical Center | 90 | 2018-03-01 | 2018-03-01 |
| Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Pasireotide LAR - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 123 | 2015-03-31 | 2019-12-10 |
| Cabergoline in Nonfunctioning Pituitary Adenomas Cabergoline - Pituitary Adenoma, Nonfunctioning Pituitary Adenoma | Phase 3 | Completed | University of Sao Paulo General Hospital | 140 | 2015-02-01 | 2017-09-07 |
| Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Gallium-68 DOTATOC PET - Pituitary Tumours | Phase 3 | Terminated | Göteborg University | 22 | 2015-01-01 | 2022-03-31 |
| Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas cabergoline - Pituitary Neoplasms, Adenoma | Phase 3 | Active not recruiting | St. Olavs Hospital | 60 | 2014-11-01 | 2026-07-21 |
| An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Pasireotide sub-cutaneous - Cushing's Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 104 | 2011-08-16 | 2018-06-19 |
| Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 198 | 2010-07-19 | 2018-04-05 |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Pasireotide, cabergoline - Non-functioning Pituitary Adenomas, Prolactinomas | Phase 2 / Phase 3 | Completed | Universidade Federal do Rio de Janeiro | 21 | 2010-03-01 | 2016-08-22 |
| Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Cabergoline - Cushing's Disease, Corticotroph Adenoma | Phase 3 | Completed | Seth Gordhandas Sunderdas Medical College | 2007-11-01 | 2009-04-29 |
Acromegaly (5) · Pituitary ACTH Hypersecretion (3) · Adenoma (2) · Growth Hormone-Secreting Pituitary Adenoma (2) · Pituitary Diseases (2) · Prolactinoma (2) · ACTH-Secreting Pituitary Adenoma (1) · Gigantism (1) · Growth Disorders (1) · Hyperprolactinemia (1)
Brain Diseases (12) · Central Nervous System Diseases (12) · Endocrine Gland Neoplasms (12) · Endocrine System Diseases (12) · Hypothalamic Diseases (12) · Neoplasms (12) · Neoplasms by Site (12) · Nervous System Diseases (12) · Pituitary Diseases (10) · Brain Neoplasms (9) · Central Nervous System Neoplasms (9) · Hypothalamic Neoplasms (9) · Nervous System Neoplasms (9) · Supratentorial Neoplasms (9) · Hyperpituitarism (8)
Cabergoline (5) · pasireotide (3) · Injections (1) · Proton Therapy (1) · Radiosurgery (1) · Radiotherapy (1) · Radiotherapy, Intensity-Modulated (1) · Solutions (1) · Temozolomide (1) · lanreotide (1)
Novartis Pharmaceuticals (3) · University of Sao Paulo General Hospital (2) · Göteborg University (1) · Peking Union Medical College Hospital (1) · Samsung Medical Center (1) · Seth Gordhandas Sunderdas Medical College (1) · St. Olavs Hospital (1) · Universidade Federal do Rio de Janeiro (1) · University College, London (1)
Brazil (6) · Romania (3) · Argentina (2) · Belgium (2) · Colombia (2) · France (2) · Germany (2) · Italy (2) · Norway (2) · Russia (2) · South Korea (2) · Spain (2) · Sweden (2) · Turkey (Türkiye) (2) · United Kingdom (2)
Michael Kosmin (1) · Nalini S Shah, DM (1) · Rafael L Batista, MD (1) · Sven M Carlsen, prof md (1)
PMID 25260838, PMID 25418156, PMID 27150495, PMID 30540568, PMID 31379734, PMID 32117045, PMID 32217809, PMID 35954244, PMID 36856733
2014 (1)